Rilpivirine in Virologically Suppressed Adolescents

A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

NCT04012931 ·Status: COMPLETED ·Phase: PHASE2

A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies

NCT02494986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study

NCT01679964 ·Status: COMPLETED ·Phase: PHASE4

Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure

NCT01189695 ·Status: COMPLETED ·Phase: PHASE4

TDM of Generic Lopinavir/Ritonavir 200/50 mg

NCT00802334 ·Status: COMPLETED ·Phase: PHASE2

Atazavanir/Ritonavir-based HAART in Children

NCT01656109 ·Status: COMPLETED ·Phase: PHASE2

A PK and Salvage Study for Children With HIV-infection

NCT00476359 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens

NCT00886990 ·Status: COMPLETED

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

NCT02652624 ·Status: COMPLETED ·Phase: PHASE3

Lopinavir (LPV) Dose Reduction

NCT01159275 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients

NCT01335698 ·Status: COMPLETED ·Phase: PHASE3

Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women

NCT00621166 ·Status: COMPLETED ·Phase: PHASE2

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

NCT01620944 ·Status: TERMINATED ·Phase: PHASE3

Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy

NCT00357552 ·Status: COMPLETED ·Phase: NA

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

NCT01307488 ·Status: COMPLETED ·Phase: PHASE4

Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.

NCT01237444 ·Status: COMPLETED ·Phase: PHASE3

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

NCT00120393 ·Status: COMPLETED ·Phase: PHASE3

TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV

NCT01281813 ·Status: COMPLETED ·Phase: PHASE3

A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

NCT00144105 ·Status: TERMINATED ·Phase: PHASE2

Test Albuvirtide in Experienced Patients

NCT02369965 ·Status: COMPLETED ·Phase: PHASE3

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

NCT00933205 ·Status: APPROVED_FOR_MARKETING

Dose Reduction of Lopinavir in Children

NCT00887120 ·Status: COMPLETED ·Phase: PHASE2

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

NCT00654147 ·Status: COMPLETED ·Phase: PHASE2

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

NCT01332227 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

NCT01705574 ·Status: COMPLETED ·Phase: PHASE3